54 213 54 213
Pill imprint 54 213 54 213 has been identified as Lithium carbonate 150 mg.
Lithium is used in the treatment of bipolar disorder; schizoaffective disorder; mania; cluster headaches and belongs to the drug class miscellaneous antipsychotic agents. There is positive evidence of human fetal risk during pregnancy.
Lithium 150 mg is not subject to the Controlled Substances Act.
See also related documents.
Lithium carbonate Images
- Imprint:
-
54 213
54 213 - Strength:
- 150 mg
- Color:
- White
- Size:
- 4.00 mm
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Inactive Ingredients:
- FD&C Red No. 40
gelatin
sodium lauryl sulfate
magnesium silicate
titanium dioxide
ferrosoferric oxide
povidone k30
shellac
- Drug Class:
- Miscellaneous antipsychotic agents
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- Roxane Laboratories, Inc.
- National Drug Code (NDC):
- 00054-8526
| NDC Code | Manufacturer / Repackager |
|---|---|
| 00054-2526 | Roxane Laboratories,Inc. |
Note: Inactive ingredients may vary.
Advertisement
More Lithium Carbonate resources
- Lithium
- Lithium (Wolters Kluwer)
- Lithium Controlled-Release and Extended-Release Tablets (Wolters Kluwer)
- Lithium Syrup (Wolters Kluwer)
- lithium (Cerner Multum)
- lithium (Micromedex) - Includes Dosage Information
- Lithium Salts (AHFS DI)
- Lithane (FDA)
- Lithium (FDA)
- Lithium Capsules (FDA)
- Lithium Carbonate (FDA)
- Lithium Carbonate Tablets (FDA)
- Lithium Citrate Syrup (FDA)
- Lithium ER (FDA)
- Lithium Oral Solution (FDA)
- Lithium (Wolters Kluwer)
Search Again
